Safety Study of ExAblate for the Treatment of Uterine Fibroids

Uterine Fibroids Clinical Trial

Official title:

A Phase IV Clinical Study To Evaluate the Safety of MR-Guided Focused Ultrasound Treatment of Uterine Fibroids With Enhanced Sonication Techniques

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01142791
• Other study ID #: UF033
• Status: Completed
• Phase: N/A
• Start date: May 2010
• Est. completion date: April 2012

Study information

• Verified date: January 2019
• Source: InSightec
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objective of this Phase IV study is to evaluate the safety of the ExAblate treatment of uterine fibroids using the enhanced sonication techniques, based on the current commercially-approved treatment guidelines. Treatment may include up to 100% of individual fibroid volume, within established serosal and sacral treatment margins.

The Enhanced sonication is one of the various sonication modes that may lead to increased thermal dose volume of each sonication without additional safety risks. This is an additional treatment tool available in the ExAblate system for the treatment of uterine fibroids.

The safety profile of the Enhanced Sonication was investigated under an FDA-regulated IDE study. FDA granted approval of Enhanced Sonication with the requirement to perform a post-approval study to collect additional safety data when treating up to 100% of individual fibroid volume.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 121
• Est. completion date: April 2012
• Est. primary completion date: April 2012
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Women age 18 or older

• Symptomatic uterine fibroids, defined as those resulting in scores of 21 or higher, based on patient responses to questions 1-8 of the Uterine Fibroid Symptom and Health-Related Quality of Life Questionnaire (UFS-QOL)

• Women who have given written informed consent

• Women who are able and willing to attend all study visits.

• Patient is pre or peri-menopausal (within 12 months of last menstrual period).

• Patient should be family complete.

• Able to communicate sensations during the ExAblate procedure.

• Uterine fibroids, which are device accessible (i.e., positioned in the uterus such that they can be accessed without being shielded by bowel or bone).

• Fibroids(s) clearly visible on non-contrast MRI.

• Fibroid enhances on MR contrast imaging.

Exclusion Criteria:

• Women who are pregnant, as confirmed by serum/urine test at time of screening, or urine pregnancy test on the day of treatment.

• Patients who are breast-feeding.

• Patients with active pelvic inflammatory disease (PID).

• Patients with active local or systemic infection.

• Patients experiencing chronic leg or lower back pain within the last 6 months.

• Contraindication for MRI Scan:

• Severe claustrophobia that would prevent completion of procedure in the MR unit

• Weight greater than 250 lbs (113Kg)

• Implanted ferromagnetic materials and/or devices contraindicated for MR scan

• Known intolerance to MRI contrast agent (e.g. Gadolinium or Magnevist)

• Any other contraindication for MRI Scan

• Extensive abdominal scarring in the beam path (that cannot be avoided by redirection of the beam).

• Dermoid cyst of the ovary anywhere in the treatment path.

• Known or suspected pelvic carcinoma or pre-malignant conditions, including sarcoma and adenomatous hyperplasia.

• Intrauterine device (IUD) anywhere in the treatment path.

• Undiagnosed vaginal bleeding.

• Pedunculated fibroids.

• Uterine size >24 weeks.

Related Conditions & MeSH terms

• Leiomyoma
• Uterine Fibroids

Intervention

Device:
• ExAblate
Magnetic resonance image-guided focused ultrasound (MRgFUS) for fibroid ablation

Locations

Country	Name	City	State
United States	University Image Guided Therapy	Boca Raton	Florida
United States	University of Virginia Health System	Charlottesville	Virginia
United States	Duke University	Durham	North Carolina
United States	The Methodist Hospital Research Institute	Houston	Texas
United States	Borgess Research Institute	Kalamazoo	Michigan
United States	UCLA	Los Angeles	California
United States	UCSD Department of Radiology	San Diego	California
United States	University of California San Francisco	San Francisco	California

Sponsors (1)

Lead Sponsor	Collaborator
InSightec

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percent Occurrence of Chronic Leg Pain	The hypothesis was that over 90% of subjects would not experience chronic leg pain. A lower 95% Confidence Limit > 0.90 was considered statistically successful.	From treatment to 1-month post-treatment

External Links

•   Sponsor's Web Page